For the last six weeks the shadow of potential layoffs has hung over Repare Therapeutics’ employees. Monday, staff learned that three-quarters of them are heading for the exits.
With Lava Therapeutics still smoldering from the decision to dump its lead blood cancer drug, the biotech is now laying off 30% of its staff in an effort to conserve cash.
Researchers must navigate complex regulations to ensure compliance. Join BioIVT’s experts for an insightful webinar discussing important regulations and considerations... Watch Now >>
Ryvu Therapeutics is shrinking its head count by 30% as the Polish biotech focuses its funds on taking its lead blood cancer drug through phase 3 trials.
Fortrea's CTO discusses AI's expanding role in clinical trials, from discovery to execution, and its potential to improve patient outcomes and diversity.
Regeneron’s investigational gene therapy has been tied to notable hearing improvements in 10 of 11 children who were treated for a rare genetic condition that causes hearing loss.
Kiniksa Pharmaceuticals is stopping development of a midphase autoimmune asset and returning a drug candidate to AstraZeneca as it doubles down on its cardiovascular disease pipeline.
BioCity Biopharma’s selective endothelin receptor type A antagonist has reduced excess proteins in the urine of patients with diabetic kidney disease, hitting a primary endpoint of a phase 2 trial.
After hundreds of FDA employees were suddenly laid off last weekend, including dozens at the agency’s device center, the government has begun rescinding some of those cuts and attempting to rehire lost workers.
Researchers studying a deadly virus discovered a key protein behind its lethality and successfully used antibodies to stop that protein from causing dangerous fluid leakage in mice.
HHS secretary Robert F. Kennedy Jr. has been on the receiving end of two heated letters from lawmakers outlining the threats to innovation posed by mass firings at U.S. health agencies.
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. Of the world’s 22 biopharma companies that have reported quarterly revenues of at least $2 billion, only one posted a year-over-year decline. And that decline came with a caveat.
Elon Musk is facing a lawsuit from federal workers over a mass email requiring government employees to list productive tasks from the prior week or risk termination. HHS leadership instructed staff a response is voluntary, with a new set of guidelines to follow.
This week on "The Top Line," we dive into several of the biggest failures in clinical-stage drug development last year and discuss what the biopharma industry can learn from these setbacks.
